<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
<channel>
  <title>Nyheter om: Imaging</title>
  <link>https://www.pressen.se/</link>
  <description>På Pressen.se kan du söka efter artiklar i svenska medier.</description>
    <pubDate>Tue, 21 Apr 2026 13:00:00 GMT</pubDate>
  <item>
    <title>Arcoma AB utser Mattias Guldstrand till Chief Technology Officer</title>
    <pubDate>Tue, 21 Apr 2026 13:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1304047294.html</link>
    <description>PRESSRELEASE  2026-04-21  Arcoma AB utser Mattias Guldstrand till Chief Technology Officer  Arcoma AB (publ) har utsett Mattias Guldstrand till Chief Technology Officer (CTO). Mattias Guldstrand kommer närmast från Solutions for Tomorrow AB och DMS Imaging och har en bred erfarenhet av teknikutveckling och ledande roller inom medicinteknik.  Som CTO kommer han att ansvara för Arcomas forsknings- och utvecklingsorganisation och bidra till att ytterligare stärka bolagets tekniska och kommersiella utveckling.</description>
    <source>GlobeNewswire</source>
  </item>


  <item>
    <title>Fingerprint Cards AB (publ) genomför sin tredje IP- och licensieringsaffär på 11 månader med avtal värt 19 Mkr med PixArt Imaging Inc., plus ytterligare royalty-uppsida</title>
    <pubDate>Fri, 03 Oct 2025 06:35:00 GMT</pubDate>
    <link>https://www.pressen.se/1225756679.html</link>
    <description>Fingerprint Cards AB (FPC) meddelade idag att bolaget har genomfört sin tredje IP- och licensieringsaffär under de senaste elva månaderna genom att ingå ett avtal med PixArt Imaging Inc. (”PixArt”). Enligt avtalet överför FPC vissa tillgångar relaterade till fingeravtryckssensorteknologi och beviljar licens för vissa patent samt algoritmmjukvara för användning inom PC-tillämpningar.</description>
    <source>GlobeNewswire</source>
  </item>
  <item>
    <title>Nordic Capital investerar i målsökande cancerbehandlingar</title>
    <pubDate>Thu, 12 Jun 2025 15:04:26 GMT</pubDate>
    <link>https://www.pressen.se/1179213773.html</link>
    <description>Nordic Capital tar sikte på marknaden för målsökande cancerbehandlingar genom att bli majoritetsägare i danska Minerva Imaging.  ”Det är ett av de snabbaste växande forskningsområdena inom läkemedelsbranschen”, säger riskkapitalbolagets partner Jonas Agnblad..</description>
    <source>DI</source>
  </item>
  <item>
    <title>SyntheticMR receives FDA 510(k) clearance for SyMRI 15</title>
    <pubDate>Fri, 06 Dec 2024 19:44:00 GMT</pubDate>
    <link>https://www.pressen.se/1105403587.html</link>
    <description>SyntheticMR, leader in quantitative imaging software, is pleased to announce that its SyMRI 15 solution has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) on diagnostic image replacement of conventional images..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Phase Holographic Imaging vill ta in 64 miljoner</title>
    <pubDate>Wed, 13 Nov 2024 05:19:37 GMT</pubDate>
    <link>https://www.pressen.se/1096037069.html</link>
    <description>Phase Holographic Imaging, PHI, har beslutat om en företrädesemission om cirka 64,3 miljoner kronor, med syftet att finansiera den strategiska utvecklingen och betala utestående lån..</description>
    <source>DI</source>
  </item>
  <item>
    <title>SyntheticMR Announces the Appointment of Francois Hebert as New President, North America</title>
    <pubDate>Wed, 04 Sep 2024 08:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1069997043.html</link>
    <description>SyntheticMR is thrilled to announce the appointment of Francois Hebert as the new President of SyntheticMR, North America. With three decades of experience in healthcare and medical imaging, Frank brings extensive expertise from his recent senior leadership roles..</description>
    <source>DI</source>
  </item>
  <item>
    <title>SyntheticMR Receives Regulatory Approval for SyMRI in Taiwan</title>
    <pubDate>Mon, 19 Aug 2024 08:48:15 GMT</pubDate>
    <link>https://www.pressen.se/1064151837.html</link>
    <description>SyntheticMR announced today that its quantitative imaging software solution, SyMRI 12, has received regulatory approval from the Taiwan Food and Drug Administration (TFDA). This milestone enables the sale and distribution of SyMRI 12 in the Taiwanese market, paving the way for regional expansion..</description>
    <source>DI</source>
  </item>
  <item>
    <title>SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI NEURO Software at SimonMed Facilities.</title>
    <pubDate>Wed, 17 Apr 2024 08:15:00 GMT</pubDate>
    <link>https://www.pressen.se/1023181319.html</link>
    <description>SimonMed Imaging (&quot;SimonMed&quot;), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of synthetic availability from SyntheticMR’s SyMRI NEURO software at its facilities..</description>
    <source>DI</source>
  </item>
  <item>
    <title>SyntheticMR receives FDA 510(k) clearance for their next Generation Solution SyMRI 3D</title>
    <pubDate>Wed, 27 Mar 2024 10:01:35 GMT</pubDate>
    <link>https://www.pressen.se/1017996646.html</link>
    <description>SyntheticMR announced today that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients</title>
    <pubDate>Fri, 01 Mar 2024 08:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1011389508.html</link>
    <description>Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and magnetic resonance imaging (MRI) software solutions company SyntheticMR (Linköping, Sweden) today announced the launch of Smart Quant Neuro 3D [1] – a major advance in objective decision support for diagnosis and therapy assessment of brain disorders like multiple sclerosis (MS), traumatic brain injury (TBI), and dementia. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare..</description>
    <source>DI</source>
  </item>
</channel>
</rss><!-- CR: cache is set: Sidan laddades på 0.18797707557678 s -->